Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared a post on LinkedIn by ImmunoRad adding:
“Great to have the opportunity to speak at ImmunoRad. I had the pleasure of presenting work that has been led by Dr Malin Pedersen in the Harrington/Melcher lab.
Malin has generated highly impressive data which we hope will soon be shared with the community through publication. This has been an amazing collaboration with colleagues at Boehringer-Ingelheim.
Quoting ImmunoRad’s post below:
“Live Feed: Pr Kevin Harrington (The Institute of Cancer Research, UK) presented a comprehensive talk about STING agonist during adjuvant immunotherapy for radiocurable cancers. He first presented the Phase 1 and 2 clinical studies on STING agonist for advanced and metastatic lymphomas. In addition, he showed some really impressive remission of H&N cancer patients.
After the 1st generation of STING agonist (intratumoral administered therapy), the novel second generation delivered with systemic administration is very promising. In particular, systemic STING agonist induces activation of murine dendritic cells in vitro and in vivo, in addition to a in a dose-dependent vaso-active effect.
In the 2nd part of the presentation, Pr Harrington talked about RT as a partner for STING agonist. Mouse models for ATC and H&N was presented in the context of in vivo combination of RT plus low-dose STING agonist.
The observed effect was not only vascular-related but also mediated by immune cells:
– CD8 depletion reduces the efficacy of the combination.
– Induction of IFN signaling and recruitment of immune cells.
– CD8 T cells are highly activated in tumors treated with RT/STING.
Finally, he presented some promising combinations, both going impressive data about the combination:
– RT/STING plus aP-D1/a-CTLA4.
– RT/STING plus aCD25 results in tumor cures.”
More posts featuring Kevin Harrington.